1. Home
  2. CUE vs JYNT Comparison

CUE vs JYNT Comparison

Compare CUE & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$25.80

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$9.22

Market Cap

118.2M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUE
JYNT
Founded
2014
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Multi-Sector Companies
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
124.5M
118.2M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
CUE
JYNT
Price
$25.80
$9.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$120.00
$17.00
AVG Volume (30 Days)
71.2K
87.2K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
61.11
133.93
EPS
N/A
0.09
Revenue
$27,466,000.00
$117,696,356.00
Revenue This Year
N/A
$12.23
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$106.44
Revenue Growth
195.75
15.49
52 Week Low
$0.17
$7.50
52 Week High
$41.42
$12.76

Technical Indicators

Market Signals
Indicator
CUE
JYNT
Relative Strength Index (RSI) 55.32 58.19
Support Level $0.30 $8.01
Resistance Level $32.60 $9.46
Average True Range (ATR) 3.67 0.47
MACD -0.48 0.08
Stochastic Oscillator 53.77 70.13

Price Performance

Historical Comparison
CUE
JYNT

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.

Share on Social Networks: